Description:
CLL is the most common form of leukemia in the western world. As the majority of patients are elderly at diagnosis and often have other medical comorbidities, this creates a challenging situation for treating oncologists. Important considerations include effective and tolerable regimens, that utilize novel mechanisms of action and can be tailored to the patient, particularly those with high-risk features. This educational session will focus on dual targeted therapeutic options for treatment naïve patients and novel agents under investigation in Richter Transformation. In addition, this session with discuss the role of minimal residual disease in the management of CLL. Dr. Chaitra S. Ujjani will discuss clinical trials leading to the approval of dual targeted regimens for the front-line treatment of CLL. She will also discuss clinical trials involving the combination of BTK and BCL2 inhibitors in previously untreated patients. Dr. Joanna M. Rhodes will discuss the role of minimal residual disease (MRD) testing in the treatment of chronic lymphocytic leukemia. A focus will be placed on data from clinical trials of targeted therapies and the role of MRD in response assessments, and its clinical utility in practice. Dr Toby A Eyre will discuss the current management and challenges of managing patients with Richter Transformation of CLL. Recent advances, clinical trial data and future developments will be discussed.